| General Information of Drug Metabolite (DM) (ID: DM006833) |
| DM Name |
Quinone
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 1A2 (CYP1A2)
|
DME0003
|
| Unclear - Unclear |
CP-122721
|
[1] , [2] |
|
Cytochrome P450 3A (CYP3A)
|
DMEN065
|
| Unclear - Unclear |
CP-122721
|
[1] , [2] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Phytonadione |
DR5202
|
Approved |
Vitamin K deficiency |
|
|
| CP-122721 |
DR1849
|
Phase 2 |
Depression |
|
|
| Pyrogallol |
DR2253
|
Investigative |
Discovery agent |
|
|
| References |
| 1 |
In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet. 2007 Oct;22(5):336-49.
|
| 2 |
Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
